Topical Antibacterial Agents for Prevention of COVID-19
Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine whether intranasal application of
aminoglycoside (Neosporin) increases local nasal innate immune responses compared to placebo
control in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Yale University
Collaborator:
Bill and Melinda Gates Foundation
Treatments:
Bacitracin zinc, neomycin sulfate, polymyxin B, drug combination Petrolatum